Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Keros Therapeutics, Inc.

Market Cap 211M 184M 170M 159M 299M 19.89B 301M 2.02B 783M 9.79B 791M 774M 33.99B P/E 2026 *
-1.78x
P/E 2027 * -1.95x
Enterprise Value 211M 184M 170M 159M 299M 19.89B 301M 2.02B 783M 9.79B 791M 774M 33.99B EV / Sales 2026 *
49.6x
EV / Sales 2027 * 11.1x
Free-Float
46.57%
Yield 2026 *
-
Yield 2027 * -
1 day+2.30%
1 week+6.30%
Current month-3.24%
1 month-2.73%
3 months-3.16%
6 months-48.99%
Current year-46.54%
1 week 9.99
Extreme 9.9928
11.04
1 month 9.69
Extreme 9.69
11.63
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 56 01/02/2020
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
06-15Buy

Chairman

1,000 0.0051%
06-11Sell

Director

-550 0.0028%
06-04Sell

Director

-2,625 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+6.30%-20.89%-73.77% 211M
+2.15%+4.05%+69.96%+118.12% 55.19B
+4.60%+3.02%+57.38%+62.27% 45.75B
-0.20%-0.04%-11.89%-15.42% 22.98B
+1.91%+1.39%-6.27%+385.82% 20.76B
-0.26%-0.58%+25.47%-18.57% 16.26B
+0.60%+3.26%+21.66%-36.79% 15.42B
-1.66%-2.56%+19.08%+159.78% 13.05B
+4.95%+11.70%+125.78%+261.94% 12.45B
-5.63%-6.39%+19.78% - 12.37B
Average +0.94%+2.65%+30.00%+93.71% 21.44B
Weighted average by Cap. +1.67%+1.51%+41.43%+106.33%

Financials

2026 *2027 *
Net sales 4.25M 3.71M 3.43M 3.21M 6.03M 401M 6.06M 40.74M 15.79M 197M 15.96M 15.62M 686M 18.91M 16.49M 15.27M 14.3M 26.81M 1.78B 26.97M 181M 70.21M 878M 70.98M 69.46M 3.05B
Net income -120M -105M -97.27M -91.06M -171M -11.37B -172M -1.15B -447M -5.59B -452M -442M -19.43B -132M -115M -107M -99.77M -187M -12.45B -188M -1.26B -490M -6.13B -495M -485M -21.28B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
87
Date Price Change Volume
22/06/26 10.88 $ +2.16% 48,075
18/06/26 10.65 $ +2.31% 400,525
17/06/26 10.41 $ +3.79% 241,766
16/06/26 10.03 $ -2.05% 264,453
15/06/26 10.24 $ +0.89% 347,725
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.65USD
Average target price
21.83USD
Spread / Average Target
+105.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!